Preclinical study demonstrates the potential of mRNA-encoded immune modulators delivered via lipid nanoparticles to enhance anti-tumor immunity and overcome immunotherapy resistance
The service aims to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.
The novel lipid nanoparticles for mRNA delivery will enhance thermostability, biodegradability and safety, paving the way for new off-the-shelf therapies
The tripartite mRNA technology has completed its phase 1b study for direct, intranodal injections in adjuvant melanoma patients
